Biomarkers to predict cardiovascular disease in people living with HIV

Curr Opin Infect Dis. 2022 Feb 1;35(1):15-20. doi: 10.1097/QCO.0000000000000802.

Abstract

Purpose of review: Cardiovascular diseases (CVD) is one of the leading cause of morbidity and mortality in antiretroviral treated people living with HIV (PWH) with risk score algorithms based on traditional risk factors being shown to be consistently unreliable in estimating risk in this population. This review aims to examine recent data published in last 18-24 months exploring biomarkers that may be useful in identifying PWH at risk of developing CVD.

Recent findings: Ongoing research explores the association of inflammatory biomarkers with subclinical CVD with few studies examining their clinical utility in improving CVD risk prediction. Further mechanistic studies explore the role of monocyte/macrophages in CVD pathogenesis with some studies examining functional assays as better predictors of CVD risk.

Summary: Although persistent associations with inflammatory markers and CVD are demonstrated, few biomarkers have emerged as being clinically useful. Large population studies are needed to assess their utility in improving CVD risk prediction in PWH.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Cardiovascular Diseases* / epidemiology
  • HIV Infections* / complications
  • Humans
  • Risk Factors

Substances

  • Biomarkers